TPO and polycystic ovary syndrome: Another subgroup analysis based on BMI-matching revealed that the higher prevalence of anti-TPO and anti-TG antibodies in women with PCOS was no longer statistically significant in the BMI-matched subgroup (anti-TPO: OR 1.61, 95% CI: [0.48–5.42], p = 0.45; anti-TG: OR 1.64, 95% CI: [0.59–4.52], p = 0.34), in contrast to the BMI-not matched subgroup (anti-TPO: OR 2.24, 95% CI: [1.49–3.38], p = 0.0001; anti-TG: OR 2.08, 95% CI: [1.25–3.45], p = 0.005).